SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF

The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research

Meir Orbach 22:1313.05.21
Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, announced on Thursday the closing of a $28.5 million series B funding round. Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round. The Cystic Fibrosis Foundation invested a total of $8.4 million, half of which is to be allocated to preclinical studies and the other half for clinical trials on humans.

 

SpliSense was founded by Prof. Batsheva Kerem, PhD, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research. Kerem was part of the research team that identified and cloned the CFTR gene. The technology was licensed from Yissum, the technology transfer office of Hebrew University.
Gili Hart, PhD, Executive Officer, SpliSense. Photo: Courtesy Gili Hart, PhD, Executive Officer, SpliSense. Photo: Courtesy

 

Proceeds from the series B financing will be used to advance the company's pipeline, including its lead Anti Sense Oligonucleotide (ASO) product which has demonstrated that it is able to completely restore Cystic Fibrosis Transmembrane conductance Regulator (CFTR) channel function in patient-derived cell cultures. The company plans to initiate a Phase 1/2a trial in 2022.

 

CF is a genetic multisystem disorder that originates from various mutations in the CFTR gene, which is responsible for the production of the CFTR protein, a chloride channel expressed, among other systems, in the lungs. SpliSense utilizes short, precisely targeted proprietary RNA stretches called ASOs to correct various mutations in the CFTR mRNA.

 

"CF is a debilitating disease, leading to frequent lung infections, breathing difficulties and reduced life expectancy. Currently available treatments focus on treating the symptoms of the disease, such as channel function and protein modulators, antibiotics to treat lung infections, or mucus thinning drugs. However, they do not treat the root cause of the disease," said Gili Hart, PhD, Executive Officer at SpliSense. "Our technology addresses the underlying genetic cause, thereby offering, for the first time, hope of restoring adequate lung function to CF patients. We look forward to using this funding and the support of the Cystic Fibrosis Foundation to advance our pipeline for the benefit of CF patients."

 

Dr. Nissim Darvish, MD, Chairman of the Board of SpliSense, "SpliSense couples Prof. Kerem's pioneering research on the genetic underpinnings of CF together with a strong track record in developing ASO therapies and inhaled treatments. We have great faith in SpliSense's transformative technology for the genetic treatment of CF and await with interest the advancement of its pipeline into the clinic, as well as its expansion to additional indications."